Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label studyJesús G. Berdeja, Sundar Jagannath, Tzu‐Min Yeh et al.|The Lancet|2021Cited by 1.7k
CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple MyelomaDeepu Madduri, Thomas Martin, Jesús G. Berdeja et al.|Blood|2020Cited by 94
Health-Related Quality of Life in the Cartitude-1 Study of Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple MyelomaThomas Martin, Sundar Jagannath, Yi Lin et al.|Blood|2020Cited by 11
Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel in the Phase 1b/2 CARTITUDE-1 StudyYi Lin, Sundar Jagannath, Thomas Martin et al.|Blood|2020Cited by 9
Patient Expectations and Perceptions of Treatment in CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple MyelomaAdam D. Cohen, Sundar Jagannath, Parameswaran Hari et al.|Blood|2020Cited by 7